I think 1:10 is unrealistic given they originally offered 1:17 (now effectively 1:21 post dilution). They're more likely to cap the next round at sub $150M (from $113M) as they may not want to use significant levels of debt to get T3 up and running
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025